Value202320242025TTMSelling/general/admin expenses6.14 B6.33 B6.09 B6 BResearch & development399 M408 M382 M367 MOperating income2.51 B1.84 B2.41 B2.62 BNon-Operating Income, Total-72 M-48 M-36 M-30 MInterest expense, net of interest capitalized250 M431 M430 M429 MNon-Operating Income, excl. Interest Expenses-308 M-52 M-476 M-469 MUnusual income/expense-14 M4 M10 M—Pretax income2.19 B1.42 B2 B2.21 BEquity in earnings————Taxes526 M385 M529 M591 MNon-controlling/minority interest————After tax other income/expense-6 M-69 M-67 M-69 MNet income before discontinued operations1.66 B1.03 B1.47 B1.62 BDiscontinued operations————Net income1.66 B1.03 B1.47 B1.62 BDilution adjustment————Preferred dividends————Diluted net income available to common stockholders1.66 B1.03 B1.47 B1.62 BBasic earnings per share (Basic EPS)0.90.540.770.85Diluted earnings per share (Diluted EPS)0.90.540.760.84Average basic shares outstanding1.85 B1.92 B1.92 B—Diluted shares outstanding1.85 B1.92 B1.92 B—EBITDA2.35 B1.49 B1.98 B1.82 BEBIT1.2 B860 M1.42 B1.26 BCost of revenue6.8 B6.5 B6.33 B6.37 BOther cost of goods sold————Depreciation & amortization (cash flow)627 M622 M557 M564 M
Kenvue Inc. Common Stock
Kenvue Inc. is an American consumer health company. Formerly the Consumer Healthcare division of Johnson & Johnson, Kenvue owns well-known brands such as Aveeno, Band-Aid, Benadryl, Combantrin, Zyrtec, Johnson's, Listerine, Lactaid, Mylanta, Neutrogena, Trosyd, Calpol, Tylenol, and Visine. Kenvue is incorporated in Delaware and was originally headquartered in the Skillman section of Montgomery Township, New Jersey, before relocating to Summit, New Jersey.
Johnson & Johnson announced in November 2021 that it would spin off its consumer health division as a separate company. The new company was named Kenvue in September 2022, and its initial public offering took place in May 2023, raising $3.8 billion in the largest U.S. IPO since 2021, with an initial valuation of about $41 billion. Johnson & Johnson initially retained more than 90% ownership before completing a full separation through a share exchange in July 2023. Kenvue was subsequently added to the S&P 500 Dividend Aristocrats index.
CEO Thibaut Mongon initially led Kenvue, which employed about 22,200 people in 2022. Following Mongon’s termination in 2025, Kirk Perry was named interim CEO.